Effects of ranibizumab and zoledronic acid on endometriosis in a rat model

Eda Ureyen Ozdemir, Eda Üreyen Özdemir, Ertan Adali, Ertan Adalı, Mine Islimye Taskin, Mine İslimye Taşkın, Altug Yavasoglu, Altuğ Yavaşoğlu, Huseyin Aktug, Hüseyin Aktuğ, Fatih Oltulu, Umit Inceboz, Ümit İnceboz
Archives of gynecology and obstetrics · 2022 · vol. 306(4) , pp. 1399–1405 · doi:10.1007/s00404-021-06393-0 · PMID:35212768 · W4225340262
letter OA: closed CC0 ⤵ 2 in-corpus citations
Limited metadata. Only one source feed has indexed this record so far — no abstract, full text, or open-access copy is available through Endo Lab. The publisher's page (linked below) is the canonical location for the actual content. If you have institutional access, use "Find at my library".
View at publisher → View on OpenAlex View on PubMed

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Bone Density Conservation Agents Bone Density Conservation Agents Bone Density Conservation Agents Endometriosis Endometriosis Animals Female Humans Ranibizumab Rats Zoledronic Acid

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (30)

Cited by (2)

Source provenance

europepmc
last seen: 2026-06-12T06:13:51.797165+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:23:57.700195+00:00
unpaywall
last seen: 2026-06-02T02:00:03.124865+00:00
License: CC0 · commercial use OK